Myeloma Paper of the Day, June 4th, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: Phase III BENEFIT trial shows addition of bortezomib to isatuximab/lenalidomide/dexamethasone for transplant-ineligible myeloma patients improves CR rate (33% vs. 58%) and MRD-negativity (26% vs. 53%)(the primary endpoint).”
Source: Robert Orlowski/X
Authors: Xavier Leleu, et al.
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
